Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Amoxapine
Drug ID BADD_D00128
Description Amoxapine, the N-demethylated derivative of the antipsychotic agent loxapine, is a dibenzoxazepine-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, amoxapine does not affect mood or arousal, but may cause sedation. In depressed individuals, amoxapine exerts a positive effect on mood. TCAs are potent inhibitors of serotonin and norepinephrine reuptake. In addition, TCAs down-regulate cerebral cortical β-adrenergic receptors and sensitize post-synaptic serotonergic receptors with chronic use. The antidepressant effects of TCAs are thought to be due to an overall increase in serotonergic neurotransmission. TCAs also block histamine H1 receptors, α1-adrenergic receptors and muscarinic receptors, which accounts for their sedative, hypotensive and anticholinergic effects (e.g. blurred vision, dry mouth, constipation, urinary retention), respectively. See toxicity section below for a complete listing of side effects. Amoxapine may be used to treat neurotic and reactive depressive disorders, endogenous and psychotic depression, and mixed symptoms of depression and anxiety or agitation.
Indications and Usage For the relief of symptoms of depression in patients with neurotic or reactive depressive disorders as well as endogenous and psychotic depressions. May also be used to treat depression accompanied by anxiety or agitation.
Marketing Status approved
ATC Code N06AA17
DrugBank ID DB00543
KEGG ID D00228
MeSH ID D000657
PubChem ID 2170
TTD Drug ID D09IOI
NDC Product Code 0591-5716; 0591-5714; 0591-5715; 0591-5713; 53296-0018
UNII R63VQ857OT
Synonyms Amoxapine | 2-Chloro-11-(1-piperazinyl)dibenz(b,f)(1,4)oxazepine | Desmethylloxapine | CL-67,772 | CL 67,772 | CL67,772 | Demolox | Asendin | Défanyl | Asendis
Chemical Information
Molecular Formula C17H16ClN3O
CAS Registry Number 14028-44-5
SMILES C1CN(CCN1)C2=NC3=CC=CC=C3OC4=C2C=C(C=C4)Cl
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal pain07.01.05.002--
Accommodation disorder06.02.04.001--Not Available
Agitation19.06.02.001; 17.02.05.012--
Agranulocytosis01.02.03.001--Not Available
Alopecia23.02.02.001--
Anxiety19.06.02.002--
Arrhythmia supraventricular02.03.03.001--Not Available
Asthenia08.01.01.001--Not Available
Ataxia17.02.02.001; 08.01.02.004--
Atrial fibrillation02.03.03.002--
Atrioventricular block02.03.01.002--Not Available
Blood glucose abnormal13.02.02.008--Not Available
Blood prolactin increased13.10.03.002--Not Available
Body temperature increased13.15.01.001--Not Available
Breast enlargement21.05.04.001--Not Available
Cerebrovascular accident24.03.05.001; 17.08.01.007--
Confusional state19.13.01.001; 17.02.03.005--
Constipation07.02.02.001--
Coordination abnormal17.02.02.004--Not Available
Delusion19.10.01.001--
Dermatitis23.03.04.002--Not Available
Diarrhoea07.02.01.001--
Disorientation19.13.01.002; 17.02.05.015--Not Available
Disturbance in attention17.03.03.001; 19.21.02.002--
Dizziness02.11.04.006; 24.06.02.007; 17.02.05.003--
Dry mouth07.06.01.002--
Dysgeusia17.02.07.003; 07.14.03.001--
Dyspepsia07.01.02.001--
Electroencephalogram abnormal13.07.03.001--Not Available
Eosinophilia01.02.04.001--
The 1th Page    1 2 3 4    Next   Last    Total 4 Pages